SOUTH
SAN FRANCISCO, Calif., Oct. 27,
2023 /PRNewswire/ -- IDEAYA Biosciences, Inc.
(Nasdaq:IDYA) today announced the closing of its underwritten
public offering of 5,797,872 shares of its common stock at a public
offering price of $23.50 per share,
before underwriting discounts and commissions, and pre-funded
warrants to purchase 319,150 shares of common stock at a public
offering price of $23.4999 per
pre-funded warrant, before underwriting discounts and commissions.
This includes the exercise in full by the underwriters of their
option to purchase up to an additional 797,872 shares of common
stock in the offering. The gross proceeds from the offering, before
deducting underwriting discounts and commissions and other offering
expenses payable by IDEAYA, were approximately $143.8
million.
J.P. Morgan, Goldman Sachs & Co. LLC, Jefferies and RBC
Capital Markets acted as joint book-running managers for the
offering.
The public offering was made by IDEAYA pursuant to an
automatically effective shelf registration statement on Form S-3
that was previously filed with the U.S. Securities and
Exchange Commission, or the SEC. The offering was made only by
means of a written prospectus and prospectus supplement that form a
part of the registration statement. A final prospectus supplement
and accompanying prospectus relating to the offering has been filed
with the SEC and is available on the SEC's website
at http://www.sec.gov. Copies of the final prospectus
supplement and the accompanying prospectus relating to the offering
may also be obtained by request from: J.P. Morgan, by mail at J.P.
Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY
11717, or by telephone at 866-803-9204, or by email at
prospectus-eq_fi@jpmorganchase.com; Goldman Sachs & Co. LLC by
mail at Goldman Sachs & Co. LLC, Attention: Prospectus
Department, 200 West Street, New York, NY 10282, or by
telephone at 866-471-2526, or by email
at prospectus-ny@ny.email.gs.com; Jefferies, by mail at
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, New York, NY
10022, or by telephone at 877-547-6340 or 877-821-7388, or by email
at Prospectus_Department@Jefferies.com; or RBC Capital Markets, by
mail at RBC Capital Markets, LLC, Attention: Equity Capital
Markets, 200 Vesey Street, 8th Floor, New York, NY 10281, or by telephone at
877-822-4089, or by email at equityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
___________________
About IDEAYA Biosciences
IDEAYA is a precision medicine focused oncology company
committed to the discovery and development of targeted therapeutics
for patient populations selected using molecular diagnostics.
IDEAYA's approach integrates capabilities in identifying and
validating translational biomarkers with drug discovery to select
patient populations most likely to benefit from its targeted
therapies. IDEAYA is applying its early research and drug discovery
capabilities to synthetic lethality – which represents an emerging
class of precision medicine targets.
___________________
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-announces-closing-of-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares-301970521.html
SOURCE IDEAYA Biosciences, Inc.